Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
Status:
Terminated
Trial end date:
2008-02-18
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of an investigational compound PF-02545920 for the
treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing
symptoms associated with schizophrenia.